ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein.

abstract：PURPOSE:To gain a better understanding of the impact of postprogression survival (PPS) and post-trial anticancer therapy on overall survival (OS) in first-line pancreatic cancer patients. METHODS:A literature search identified 54 randomized trials, focusing on gemcitabine monotherapy to eliminate effects of heterogene...

journal_title：Cancer chemotherapy and pharmacology

authors： Kasuga A,Hamamoto Y,Takeuchi A,Kawasaki K,Suzuki T,Hirata K,Sukawa Y,Takaishi H,Kanai T

更新日期：2017-03-01 00:00:00

abstract：:Prostaglandins (PGs) have been shown to inhibit tumour metastases in experimental animal systems. Nafazatrom is a pyrazolinone derivative that increases endogenous prostacyclin (PGI2) and has experimental anti-cancer activity. In the present study, nafazatrom was given to 47 women with advanced breast cancer; objectiv...

journal_title：Cancer chemotherapy and pharmacology

authors： Jones AL,Powles TJ,Forgeson GV,Coombes RC

更新日期：1991-01-01 00:00:00

abstract：PURPOSE:To compare serum and urine levels of tamoxifen and metabolites after a loading dose and at the steady state. METHODS:A loading dose of 160 mg of tamoxifen was given to 14 patients with advanced breast cancer. Thereafter a regular daily dose of 30 mg of tamoxifen was given. Serum and urine levels of tamoxifen a...

journal_title：Cancer chemotherapy and pharmacology

authors： de Vos D,Slee PH,Briggs RJ,Stevenson D

更新日期：1998-01-01 00:00:00

abstract：PURPOSE:Leucovorin is commonly used as folate supplement in 5-fluorouracil-based chemotherapy, but needs to be converted to active 5,10-methylenetetrahydrofolate (methyleneTHF) intracellularly. This provides for interindividual differences. MethyleneTHF has recently been developed into the stable, distributable drug, M...

journal_title：Cancer chemotherapy and pharmacology

authors： Wettergren Y,Taflin H,Odin E,Kodeda K,Derwinger K

更新日期：2015-01-01 00:00:00

abstract：:Recent studies in human bone-marrow culture and healthy human volunteers suggest that lenograstim [glycosylated, recombinant human granulocyte colony-stimulating factor (rHuG-CSF) produced in Chinese hamster ovary (CHO) cells] has greater in vivo potency than filgrastim [nonglycosylated, methionine-extended recombinan...

journal_title：Cancer chemotherapy and pharmacology

authors： Nohynek GJ,Plard JP,Wells MY,Zerial A,Roquet F

更新日期：1997-01-01 00:00:00

abstract：INTRODUCTION:Despite the extensive clinical experience with irinotecan, significant concerns remain regarding its toxicity. In a phase I trial, we modulated irinotecan pharmacokinetics by inhibiting biliary excretion of SN-38, the active metabolite of irinotecan, using cyclosporine. The modulation appeared to decrease ...

journal_title：Cancer chemotherapy and pharmacology

authors： Desai AA,Kindler HL,Taber D,Agamah E,Mani S,Wade-Oliver K,Ratain MJ,Vokes EE

更新日期：2005-10-01 00:00:00

abstract：BACKGROUND:Inhibitors of heat shock protein (Hsp) 90 induce apoptosis in multiple myeloma (MM) cells, but the molecular mechanisms underlying this cytotoxic outcome are not clear. Here, we investigate the effect of IPI-504, a novel and highly soluble inhibitor of the Hsp90 ATPase activity, on the unfolded protein respo...

journal_title：Cancer chemotherapy and pharmacology

authors： Patterson J,Palombella VJ,Fritz C,Normant E

更新日期：2008-05-01 00:00:00

abstract：PURPOSE:Triple-negative breast cancers (TNBCs) do not derive benefit from molecular-targeted treatments such as endocrine therapy or anti-HER2 therapy because they lack those molecular targets. On the other hand, TNBCs have been shown to respond to neoadjuvant chemotherapy (NAC). In this study, we analyzed TNBC patient...

journal_title：Cancer chemotherapy and pharmacology

authors： Masuda H,Masuda N,Kodama Y,Ogawa M,Karita M,Yamamura J,Tsukuda K,Doihara H,Miyoshi S,Mano M,Nakamori S,Tsujinaka T

更新日期：2011-04-01 00:00:00

abstract：PURPOSE:BMS-310705, a novel semisynthetic derivative of epothilone B, is a tubulin-polymerization agent currently in phase I clinical trials for anticancer therapy. The in vitro and in vivo pharmacokinetics and oral bioavailability of BMS-310705 were investigated in mice, rats, and dogs. In addition, comparison of the ...

journal_title：Cancer chemotherapy and pharmacology

authors： Kamath AV,Chang M,Lee FY,Zhang Y,Marathe PH

更新日期：2005-08-01 00:00:00

abstract：:The cytotoxicity of 5-fluorouracil (5-FU) is due in part to the incorporation of the base into RNA molecules. We assessed the cytotoxicity of 5-FU in human colonic carcinoma HT-29 cells and examined mRNA activity (measured by protein biosynthesis in vivo and in vitro) and the maturation of rRNA precursors as two possi...

journal_title：Cancer chemotherapy and pharmacology

authors： Greenhalgh DA,Parish JH

更新日期：1989-01-01 00:00:00

abstract：PURPOSE:Brivanib alaninate is a prodrug of brivanib (BMS-540215), a potent oral VEGFR-2 inhibitor and is currently in development for the treatment of hepatocellular and colon carcinomas. In vitro and in vivo studies were conducted to characterize the preclinical pharmacokinetics and disposition of brivanib and brivani...

journal_title：Cancer chemotherapy and pharmacology

authors： Marathe PH,Kamath AV,Zhang Y,D'Arienzo C,Bhide R,Fargnoli J

更新日期：2009-12-01 00:00:00

abstract：PURPOSE:It remains challenging to identify patients at risk of anthracycline-induced cardiotoxicity. To better understand the different risk-stratifying approaches, we evaluated (123)I-metaiodobenzylguanidine ((123)I-mIBG) scintigraphy and its interrelationship with conventional echocardiography, 2D strain imaging and ...

journal_title：Cancer chemotherapy and pharmacology

authors： Bulten BF,Verberne HJ,Bellersen L,Oyen WJ,Sabaté-Llobera A,Mavinkurve-Groothuis AM,Kapusta L,van Laarhoven HW,de Geus-Oei LF

更新日期：2015-11-01 00:00:00

abstract：:We propose a mathematical model that takes into account a classical maximum tolerated dose (MTD) chemotherapy regimen (whose primary targets are the tumor cells) as well as a metronomic chemotherapy regimen (whose primary targets are the tumor endothelial cells) for the administration of temozolomide (Temodal(®)) in o...

journal_title：Cancer chemotherapy and pharmacology

authors： Faivre C,Barbolosi D,Pasquier E,André N

更新日期：2013-04-01 00:00:00

abstract：:Intravenous (i.v.) administration of sodium thiosulfate reduces the toxicity of cis-diamminedichloroplatinum (II) (CDDP). This effect, which allows the use of increased CDDP doses, has been exploited clinically in the intraperitoneal (i.p.) treatment of intraabdominal tumors. Recently, attempts have been made to treat...

journal_title：Cancer chemotherapy and pharmacology

authors： Aamdal S,Fodstad O,Pihl A

更新日期：1988-01-01 00:00:00

abstract：PURPOSE:To investigate the efficacy and safety of combination chemotherapy with biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin in the treatment of patients with advanced or metastatic gastric cancer. PATIENTS AND METHODS:Chemonaive patients with histologically confirmed advanced or recurrent inopera...

journal_title：Cancer chemotherapy and pharmacology

authors： Lee HJ,Cho DY,Park JC,Bae SB,Lee KT,Cho IS,Han CS,Park SY,Yun HJ,Kim S

更新日期：2009-02-01 00:00:00

abstract：PURPOSE:To determine the safety, the maximal tolerated dose, and to assess for any clinical activity of pomalidomide given to patients with advanced solid tumors. PATIENTS AND METHODS:Patients with incurable solid tumors were enrolled. Two different dosing schedules were explored. In Cohort A patients were given pomal...

journal_title：Cancer chemotherapy and pharmacology

authors： Cooney MM,Nock C,Bokar J,Krishnamurthi S,Gibbons J,Rodal MB,Ness A,Remick SC,Dreicer R,Dowlati A

更新日期：2012-11-01 00:00:00

abstract：PURPOSE:This study evaluated the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of erlotinib when combined to irinotecan and capecitabine in pre-treated metastatic colorectal cancer patients. METHODS:Five dose level combinations with irinotecan (from 180 to 240 mg/m(2), day 1, q21), capecitabine (1,...

journal_title：Cancer chemotherapy and pharmacology

authors： Bajetta E,Di Bartolomeo M,Buzzoni R,Ferrario E,Dotti KF,Mariani L,Bajetta R,Gevorgyan A,Venturino P,Galassi M

更新日期：2009-06-01 00:00:00

abstract：:The effects of adriamycin (ADR) and mitomycin C (MMC) as inhibitors of the development of bladder tumors in rats were studied. Six-week-old female F344 rats were divided into nine groups, five of which received 0.05% N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) in their drinking water for the first 4 weeks, no treatmen...

journal_title：Cancer chemotherapy and pharmacology

authors： Ohtani M,Fukushima S,Ito N,Koiso K,Niijima T

更新日期：1983-01-01 00:00:00

abstract：:Seven small- (SCLC) and four non-small-cell (NSCLC) lung cancer cell lines were used to examine the in vitro cytotoxicity of cytotoxic drugs such as (1aS-(1a alpha,8 beta,8a alpha,8b alpha]-8-[aminocarbonyl)oxy)methyl)-4,8a- dimethoxy-1,1a,2,8,8a,8b-hexahydro-7-hydroxy-5-methyl-6- nitrosoazirino(2',3':3,4)-pyrrolo-(1,...

journal_title：Cancer chemotherapy and pharmacology

authors： Horiuchi N,Nakagawa K,Sasaki Y,Minato K,Fujiwara Y,Nezu K,Ohe Y,Saijo N

更新日期：1988-01-01 00:00:00

abstract：PURPOSE:Many cell lines resistant to cisplatin (DDP) have reduced DDP accumulation. We postulated that reduced accumulation of DDP in resistant cells might be due to decreased intracellular DDP binding, leading to increased passive efflux. METHODS:The total cellular ([T-DDP]), intracellular ultrafiltrable ([F-DDP]) an...

journal_title：Cancer chemotherapy and pharmacology

authors： Chau Q,Stewart DJ

更新日期：1999-01-01 00:00:00

abstract：PURPOSE:Recently, it was shown that chrysin causes upregulation of UGT1A1 in Caco-2 intestinal cells. Therefore, we proposed that oral chrysin may reduce irinotecan (CPT-11) induced diarrhoea by shifting the SN-38G/SN-38 equilibrium towards the inactive SN-38G in the gastrointestinal mucosa. The purpose of this study w...

journal_title：Cancer chemotherapy and pharmacology

authors： Tobin PJ,Beale P,Noney L,Liddell S,Rivory LP,Clarke S

更新日期：2006-02-01 00:00:00

abstract：PURPOSE:Isobologram analysis has been widely used for evaluating the combined effect of two antitumor drugs in vitro as a pre-clinical screening test. In this study, we tried to extend two-dimensional isobologram analysis to three dimensions for evaluating the effects of a three-drug combination. METHODS:We selected t...

journal_title：Cancer chemotherapy and pharmacology

authors： Mogi H,Hasegawa Y,Watanabe A,Nomura F,Saka H,Shimokata K

更新日期：1997-01-01 00:00:00

abstract：UNLABELLED:Oxaliplatin (OPT), a third-generation platinating agent, is currently being evaluated in a phase II clinical trial in head and neck cancer patients and in a phase I clinical trial in combination with paclitaxel (TXL). PURPOSE:The aim of this study was to investigate the pharmacokinetics and biological corre...

journal_title：Cancer chemotherapy and pharmacology

authors： Liu J,Kraut E,Bender J,Brooks R,Balcerzak S,Grever M,Stanley H,D'Ambrosio S,Gibson-D'Ambrosio R,Chan KK

更新日期：2002-05-01 00:00:00

abstract：PURPOSE:Radiotherapy (RTx) has been considered as the treatment for locally advanced squamous cell carcinoma of the head and neck (SCCHN). However, with only conventional fractionation (Cfx), response rates are relatively low. In this study, we report the results of hyperfractionation (Hfx) RTx with concurrent docetaxe...

journal_title：Cancer chemotherapy and pharmacology

authors： Katori H,Tsukuda M,Watai K

更新日期：2007-08-01 00:00:00

abstract：PURPOSE:The potential use of combined therapy is under intensive study including the association between classical cytotoxic and genes encoding toxic proteins which enhanced the antitumour activity. The main aim of this work was to evaluate whether the gef gene, a suicide gene which has a demonstrated antiproliferative...

journal_title：Cancer chemotherapy and pharmacology

authors： Prados J,Melguizo C,Rama AR,Ortiz R,Segura A,Boulaiz H,Vélez C,Caba O,Ramos JL,Aránega A

更新日期：2010-05-01 00:00:00

abstract：:Imidazoacridinones are a new class of highly potent antineoplastic agents synthesised at the Technical University of Gdansk. The pharmacophoric alkyldiamine group, which is also present in anthracenediones (e.g. ametantrone, mitoxantrone), has been shown to be responsible for their antineoplastic activity. In view of ...

journal_title：Cancer chemotherapy and pharmacology

authors： Augustin E,Wheatley DN,Lamb J,Konopa J

更新日期：1996-01-01 00:00:00

abstract：PURPOSE:Although cisplatin is an important agent in non-small-cell lung cancer (NSCLC), de novo resistance is common and acquired resistance emerges rapidly during therapy. Proposed mediators of platinum resistance include the protein kinase C (PKC) signal transduction pathway and associated c-FOS overexpression. While...

journal_title：Cancer chemotherapy and pharmacology

authors： Lara PN Jr,Gandara DR,Longmate J,Gumerlock PH,Lau DH,Edelman MJ,Gandour-Edwards R,Mack PC,Israel V,Raschko J,Frankel P,Perez EA,Lenz HJ,Doroshow JH

更新日期：2001-07-01 00:00:00

abstract：:A total of 37 men with epidermoid head and neck cancer whose disease had recurred following primary treatment (surgery and/or radiotherapy) received first-line chemotherapy with ifosfamide at i.v. doses of 3 g/m2 given daily on 3 consecutive days in combination with mesna (600 mg/m2 x 3 oral daily doses on days 1-3) e...

journal_title：Cancer chemotherapy and pharmacology

authors： Martín M,Diaz-Rubio E,González Larriba JL,Casado A,Sastre J,López-Vega JM,Almenarez J,Dominguez S

更新日期：1993-01-01 00:00:00

abstract：OBJECTIVES:We evaluated whether DNA repair gene polymorphisms had an effect on clinical outcomes in metastatic/recurrent nasopharyngeal carcinoma (NPC) patients treated with cisplatin-based chemotherapy. MATERIALS AND METHODS:Clinical data of 101 patients with metastatic/recurrent NPC between 2004 and 2011 were review...

journal_title：Cancer chemotherapy and pharmacology

authors： Chen C,Wang F,Wang Z,Li C,Luo H,Liang Y,An X,Shao J,Li Y

更新日期：2013-08-01 00:00:00

abstract：:There is no argument over using epidermal growth factor receptor (EGFR) mutation status to guide the frontline treatment for advanced lung adenocarcinoma (LADC); however, the role of the testing in lung squamous cell carcinoma (LSQC) remains controversial. Currently, the guidelines/consensus statements regarding EGFR ...

journal_title：Cancer chemotherapy and pharmacology

authors： Chiu CH,Chou TY,Chiang CL,Tsai CM

更新日期：2014-10-01 00:00:00